Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-26EMA Authorised: Bysumlog (insulin lispro) — Gan & Lee Pharmaceuticals Europe GmbH
EMA authorised Bysumlog (insulin lispro) by Gan & Lee Pharmaceuticals Europe GmbH for diabetes mellitus.
-
EMA approval · 2026-08-25EMA Authorised: Ozempic (semaglutide) — Novo Nordisk A/S
The EMA has authorized Ozempic (semaglutide) from Novo Nordisk A/S for the therapeutic area of diabetes mellitus.
-
EMA approval · 2026-08-25EMA Authorised: Liraglutide STADA (liraglutide) — STADA Arzneimittel AG
The EMA authorises Liraglutide STADA (liraglutide) for diabetes mellitus, with STADA Arzneimittel AG as the marketing authorization holder.
-
EMA approval · 2026-08-21EMA Authorised: Ondibta (insulin glargine) — Sandoz GmbH
Authorisation of Ondibta (insulin glargine) by Sandoz GmbH for diabetes mellitus.
-
EMA approval · 2026-07-13EMA Authorised: Lyumjev (previously Liumjev) (insulin lispro) — Eli Lilly Nederland B.V.
Lyumjev (insulin lispro) has been authorised in the EU for diabetes mellitus, with Eli Lilly Nederland B.V. as the marketing authorisation h…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-13EMA Authorised: Abasaglar (previously Abasria) (insulin glargine) — Eli Lilly Nederland B.V.
EMA authorised Abasaglar (insulin glargine) for diabetes mellitus, with Eli Lilly Nederland B.V. as marketing authorization holder.
-
EMA approval · 2026-07-13EMA Authorised: Humalog (insulin lispro) — Eli Lilly Nederland B.V.
Humalog (insulin lispro) by Eli Lilly Nederland B.V. has been authorised for use in the European Union for diabetes mellitus.
-
EMA approval · 2026-07-10EMA Authorised: Ozempic (semaglutide) — Novo Nordisk A/S
The EMA has authorised Ozempic (semaglutide) by Novo Nordisk A/S for therapeutic use in diabetes mellitus.
-
EMA approval · 2026-07-03EMA Authorised: Zegalogue (dasiglucagon hydrochloride) — Zealand Pharma A/S
Zegalogue (dasiglucagon hydrochloride) has been authorised by the EMA for the treatment of Diabetes Mellitus.
-
EMA approval · 2026-07-01EMA Authorised: Ondibta (insulin glargine) — Gan & Lee Pharmaceuticals Europe GmbH
EMA authorised Ondibta, an insulin glargine product, for diabetes mellitus by Gan & Lee Pharmaceuticals Europe GmbH.
-
EMA approval · 2026-06-10EMA Authorised: Bysumlog (insulin lispro) — Gan & Lee Pharmaceuticals Europe GmbH
The EMA has authorised Bysumlog (insulin lispro) for diabetes mellitus, under Gan & Lee Pharmaceuticals Europe GmbH.
-
EMA approval · 2026-04-24EMA Authorised: Ondibta (insulin glargine) — Gan & Lee Pharmaceuticals Europe GmbH
EMA authorised Ondibta, a brand-name insulin glargine, for treating diabetes mellitus; Marketing Authorisation Holder is Gan & Lee Pharmaceu…
-
EMA approval · 2026-04-22EMA Authorised: Ozempic (semaglutide) — Novo Nordisk A/S
The EMA authorised Ozempic (semaglutide) from Novo Nordisk A/S for the treatment of diabetes mellitus.
-
FDA approval · 2026-03-26FDA Approved: AWIQLI — Original Application (Novo Nordisk)
FDA approved AWIQLI (INSULIN ICODEC-ABAE) from Novo Nordisk through an original application, adding a new insulin product to the market. The…
-
EMA approval · 2026-03-11EMA Authorised: Kirsty (previously Kixelle) (insulin aspart) — Biosimilar Collaborations Ireland Limited
EMA authorised Kirsty, a biosimilar insulin aspart product for diabetes mellitus, marketed by Biosimilar Collaborations Ireland Limited (pre…
-
EMA approval · 2026-03-05EMA Authorised: Toujeo (previously Optisulin) (insulin glargine) — Sanofi-aventis Deutschland GmbH
The European Medicines Agency authorised Toujeo, a long-acting insulin glargine product, for diabetes mellitus with Sanofi-aventis Deutschla…
-
EMA approval · 2026-03-05EMA Authorised: Insuman (Insulin human) — Sanofi-aventis Deutschland GmbH
The European Medicines Agency authorised Insuman (insulin human) by Sanofi-aventis Deutschland GmbH for the treatment of diabetes mellitus.
-
EMA approval · 2026-03-05EMA Authorised: Apidra (insulin glulisine) — sanofi-aventis Deutschland GmbH
EMA authorised Apidra, insulin glulisine, for diabetes mellitus with sanofi-aventis Deutschland GmbH as the marketing authorisation holder.
-
EMA approval · 2026-03-05EMA Authorised: Lantus (insulin glargine) — sanofi-aventis Deutschland GmbH
The EMA authorised Lantus (insulin glargine) by sanofi-aventis Deutschland GmbH for diabetes mellitus; decision date 05/03/2026.
-
EMA approval · 2026-02-20EMA Authorised: Semglee (insulin glargine) — Biosimilar Collaborations Ireland Limited
EMA authorized Semglee as a biosimilar insulin glargine for diabetes mellitus. The marketing authorization holder is Biosimilar Collaboratio…
-
EMA approval · 2026-02-06EMA Authorised: Insulin aspart Sanofi (insulin aspart) — Sanofi Winthrop Industrie
The European Medicines Agency authorised Sanofi Winthrop Industrie's insulin aspart for the treatment of diabetes mellitus.
-
EMA approval · 2026-01-29EMA Authorised: Insulin lispro Sanofi (insulin lispro) — Sanofi Winthrop Industrie
The EMA authorised a medicinal product insulin lispro Sanofi for diabetes mellitus, with Sanofi Winthrop Industrie as the marketing authoriz…
-
EMA approval · 2026-01-26EMA Authorised: Zegalogue (dasiglucagon hydrochloride) — Zealand Pharma A/S
The EMA has authorised Zegalogue (dasiglucagon hydrochloride) from Zealand Pharma A/S for the emergency treatment of severe hypoglycaemia in…
-
FDA approval · 2026-01-23FDA Approved: AFREZZA — Supplemental Application (Mannkind Corporation)
FDA approved a supplemental application for AFREZZA (insulin human) submitted by Mannkind Corporation.
-
EMA approval · 2026-01-21EMA Authorised: Lyumjev (previously Liumjev) (insulin lispro) — Eli Lilly Nederland B.V.
EMA authorised Lyumjev (insulin lispro) by Eli Lilly Nederland B.V. for the treatment of diabetes mellitus.